The role of aspirin as antiaggregant therapy in primary prevention. An update

Aspirin indication in primary prevention has been questioned in the last ten years due to the publication of several trials with neutral outcomes. In the last year, three research studies discussed in this review (ASCEND, ARRIVE, ASPREE) have weighed the benefit (cardiovascular events reduction) aga...

Full description

Saved in:
Bibliographic Details
Published inMedicina clinica Vol. 153; no. 8; p. 326
Main Authors Jiménez-García, Nicolás, de la Torre Lima, Javier, García Alegría, Javier
Format Journal Article
LanguageEnglish
Spanish
Published Spain 25.10.2019
Subjects
Prevención primaria
Aspirina
Cardiovascular events
Hemorragias
Aspirin
Primary prevention
Antiaggregation
Eventos cardiovasculares
Antiagregación
Bleedings
Online AccessGet more information

Cover

More Information
Summary:Aspirin indication in primary prevention has been questioned in the last ten years due to the publication of several trials with neutral outcomes. In the last year, three research studies discussed in this review (ASCEND, ARRIVE, ASPREE) have weighed the benefit (cardiovascular events reduction) against the adverse effects (especially bleeding) in several situations such as general population with moderate cardiovascular risk, diabetics and elderly population. This review performs a detailed analysis of these trials and it also comments on a recent metanalysis that includes these projects along with others undertaken in the last 30 years. In addition, the current position of aspirin in primary prevention is established based on the latest evidence reviewed.
ISSN:1578-8989
DOI:10.1016/j.medcli.2019.05.024